Cargando…

Blood Transfusion Vs. Hydroxyurea for Stroke Prevention in Children With Sickle Cell Anemia: A Systematic Review and Meta-Analysis

Sickle cell anemia (SCA) is a hereditary condition that can lead to severe complications in children such as acute coronary syndrome, splenic sequestration, renal failure, and stroke. Blood transfusion and hydroxyurea (HU) therapy are used to prevent stroke in children with sickle cell disease (SCD)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hafiz, Tamara A, Aldharman, Sarah S, AlSubaie, Ruby N, Alzahrani, Lena D, Albalawi, Ibrahim Ahmed J, Alali, Yara A, Yousuf, Maisaa M, Alharbi, Hayat M, Alamri, Nawaf S, Jamil, Syed F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Pediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774052/ https://www.ncbi.nlm.nih.gov/pubmed/36569706 http://dx.doi.org/10.7759/cureus.31778

Ejemplares similares

Hydroxyurea and sickle cell anemia: effect on quality of life
por: Ballas, Samir K, et al.
Publicado: (2006)

The influence of hydroxyurea on oxidative stress in sickle cell anemia
por: Torres, Lidiane de Souza, et al.
Publicado: (2012)

Comment on "The influence of hydroxyurea on oxidative stress in sickle cell anemia"
por: van Beers, Eduard Johannes, et al.
Publicado: (2012)

Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia
por: Keikhaei, Bijan, et al.
Publicado: (2016)

Hydroxyurea treatment for adult sickle cell anemia patients in Kinshasa
por: Kabuyi, Paul Lumbala, et al.
Publicado: (2023)

O-01: HYDROXYUREA REDUCES THE TRANSFUSION BURDEN IN CHILDREN WITH SICKLE CELL ANEMIA IN SUB-SAHARAN AFRICA: THE REACH EXPERIENCE
por: A., POWER-HAYS, et al.
Publicado: (2022)

Genetic and biochemical markers of hydroxyurea therapeutic response in sickle cell anemia
por: Silva, Danilo Grunig Humberto, et al.
Publicado: (2013)

Menopause in Brazilian women with sickle cell anemia with and without hydroxyurea therapy
por: Queiroz, Ana Mach, et al.
Publicado: (2021)

Intensive hydroxyurea dosing in very young children with sickle cell anemia
por: Wang, Winfred C., et al.
Publicado: (2023)

The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea
por: da Silva, Luiz Bernardino Lima, et al.
Publicado: (2012)

Neurological Complications following Blood Transfusions in Sickle Cell Anemia
por: Alharbi, Hana, et al.
Publicado: (2017)

Comment on "The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea"
por: Souza, José Carlos, et al.
Publicado: (2012)

P-039: ALTERNATIVE DOSING AND PREVENTION OF TRANSFUSIONS (ADAPT): A PROSPECTIVE TRIAL EVALUATING TRANSFUSION UTILIZATION AND THE FEASIBILITY OF PHARMACOKINETIC HYDROXYUREA DOSING IN CHILDREN WITH SICKLE CELL ANEMIA IN UGANDA
por: POWER-HAYS, A., et al.
Publicado: (2022)

Side effects of hydroxyurea in patients with Thalassemia major and thalassemia intermedia and sickle cell anemia
por: Ghasemi, A, et al.
Publicado: (2014)

From Infancy to Adolescence: Fifteen Years of Continuous Treatment With Hydroxyurea in Sickle Cell Anemia
por: Hankins, Jane S., et al.
Publicado: (2014)

Hydroxyurea Treatment for Sickle Cell Disease
por: Steinberg, Martin H.
Publicado: (2002)

Hydroxyurea treatment is associated with reduced degree of oxidative perturbation in children and adolescents with sickle cell anemia
por: Vinhaes, Caian L., et al.
Publicado: (2020)

Longitudinal analysis of cardiac abnormalities in pediatric patients with sickle cell anemia and effect of hydroxyurea therapy
por: Dhar, Arushi, et al.
Publicado: (2021)

Hydroxyurea and blood transfusion therapy for Sickle cell disease in South Asia: inconsistent treatment of a neglected disease
por: Darshana, Thamal, et al.
Publicado: (2021)

Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen
por: Paule, Ines, et al.
Publicado: (2011)

Influence of βS-globin haplotypes hydroxyurea on tumor necrosis factor-alpha levels in sickle cell anemia
por: Laurentino, Marília Rocha, et al.
Publicado: (2014)

Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub‐Saharan Africa: Rationale and Design of the REACH Trial
por: McGann, Patrick T., et al.
Publicado: (2015)

Hydroxyurea alters circulating monocyte subsets and dampens its inflammatory potential in sickle cell anemia patients
por: Guarda, Caroline C., et al.
Publicado: (2019)

Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial
por: Abdullahi, Shehu U., et al.
Publicado: (2023)

Effectiveness of Pharmacokinetic-Guided Hydroxyurea Dose Individualization in Patients with Sickle Cell Anemia: A Mini-Review
por: dos Santos Neres, Joelma Santana, et al.
Publicado: (2023)

Efficacy, safety, and pharmacokinetics of a new, ready-to-use, liquid hydroxyurea in children with sickle cell anemia
por: Rankine-Mullings, Angela, et al.
Publicado: (2023)

Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients as a function of therapeutic transfusion and hydroxyurea treatment
por: D’Alessandro, Angelo, et al.
Publicado: (2023)

Analysis of oxidative status and biochemical parameters in adult patients with sickle cell anemia treated with hydroxyurea, Ceará, Brazil
por: Teixeira Neto, Paulo Florentino, et al.
Publicado: (2011)

Protective effect of flavonoids against reactive oxygen species production in sickle cell anemia patients treated with hydroxyurea
por: Henneberg, Railson, et al.
Publicado: (2013)

Whole Exome Sequencing Identifies Novel Genes for Fetal Hemoglobin Response to Hydroxyurea in Children with Sickle Cell Anemia
por: Sheehan, Vivien A., et al.
Publicado: (2014)

Comment on “Influence of βS-globin haplotypes and hydroxyurea on tumor necrosis factor-alpha levels in sickle cell anemia”
por: de Souza Torres, Lidiane
Publicado: (2014)

Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia
por: Fitzhugh, Courtney D., et al.
Publicado: (2015)

The Effects of Hydroxyurea Therapy on the Six-Minute Walk Distance in Patients with Adult Sickle Cell Anemia: An Echocardiographic Study
por: Garadah, Taysir, et al.
Publicado: (2019)

How Hydroxyurea Alters the Gut Microbiome: A Longitudinal Study Involving Angolan Children with Sickle Cell Anemia
por: Delgadinho, Mariana, et al.
Publicado: (2022)

Effective control of sickle cell disease with hydroxyurea therapy
por: Singh, Harminder, et al.
Publicado: (2010)

Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease
por: de Oliveira, Emanuel Almeida Moreira, et al.
Publicado: (2019)

ENHANCE—(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease
por: Creary, Susan, et al.
Publicado: (2016)

Hydroxyurea Treatment in Transfusion-Dependent β-Thalassemia Patients
por: Bordbar, Mohammad Reza, et al.
Publicado: (2014)

Influence of Oxidative Stress Biomarkers and Genetic Polymorphisms on the Clinical Severity of Hydroxyurea-Free Senegalese Children with Sickle Cell Anemia
por: Gueye Tall, Fatou, et al.
Publicado: (2020)

Effects of hydroxyurea on cytotoxicity, inflammation and oxidative stress markers in neutrophils of patients with sickle cell anemia: dose-effect relationship
por: Pedrosa, Alano Martins, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0lenc4nklk6el63b9dok76eg30